168 related articles for article (PubMed ID: 31205639)
1. Langerhans Cell Histiocytosis: Single Center Experience of 25 Years.
Tuysuz G; Yildiz I; Ozdemir N; Adaletli I; Kurugoglu S; Apak H; Dervisoglu S; Bozkurt S; Celkan T
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019035. PubMed ID: 31205639
[TBL] [Abstract][Full Text] [Related]
2. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
3. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.
Kim BE; Koh KN; Suh JK; Im HJ; Song JS; Lee JW; Kang HJ; Park KD; Shin HY; Choi HS; Lee SH; Yoo KH; Sung KW; Koo HH; Jung HL; Chung NG; Cho B; Kim HK; Lyu CJ; Baek HJ; Kook H; Park JE; Park HJ; Park BK; Yoo ES; Ryu KH; Lee KS; Kim HS; Lee JM; Park ES; Yoon HS; Lee KC; Lee MJ; Lim YT; Kim HM; Park SK; Park JA; Kim SK; Park M; Lim YJ; Lee YH; Seo JJ;
J Pediatr Hematol Oncol; 2014 Mar; 36(2):125-33. PubMed ID: 24276037
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study.
Kitticharoenjit P; Supakul N; Rujkijyanont P; Traivaree C; Photia A; Monsereenusorn C
Asian Biomed (Res Rev News); 2021 Aug; 15(4):171-181. PubMed ID: 37551332
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
[TBL] [Abstract][Full Text] [Related]
10. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
[TBL] [Abstract][Full Text] [Related]
11. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
12. Serum levels of soluble interleukin 2 receptor (sIL-2R), tumor necrosis factor-alpha (TNF-α), and immunoglobulin M are correlated with the disease extent in childhood Langerhans cell histiocytosis.
Wang W; Liu X; Yang S; Peng X; Ma Y; Xiong X; Li Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11431-11442. PubMed ID: 37389594
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement.
Miao HL; Zhao AL; Duan MH; Zhou DB; Cao XX; Li J
BMC Cancer; 2020 Sep; 20(1):911. PubMed ID: 32967635
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
15. Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series.
Han D; Li F; Yahya WH; Ge R; Zhao Y; Liu B; Zhou Y; Wen Z
J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887522
[TBL] [Abstract][Full Text] [Related]
16. Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics.
Murakami I; Oh Y; Morimoto A; Sano H; Kanzaki S; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Hayashi K; Imashuku S; Gogusev J; Jaubert F; Oka T; Yoshino T
Clin Proteomics; 2015; 12(1):16. PubMed ID: 26097443
[TBL] [Abstract][Full Text] [Related]
17. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
Su M; Gao YJ; Pan C; Chen J; Tang JY
Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
[TBL] [Abstract][Full Text] [Related]
18. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
19. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
[TBL] [Abstract][Full Text] [Related]
20. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
